Effect of treatment on systemic cytokines in head and neck squamous cell carcinoma patients

Results in Immunology

Volumn 2, Issue , 2012, Pages 1-6

  Green, Victoria L ^a   Michno, Anna ^a   Greenman, John ^a   Stafford, Nicholas D ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Head and neck cancer; Multiplex sandwich ELISA; Th1 Th2; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MULTIMODALITY CANCER THERAPY; OROPHARYNX CARCINOMA; PARANASAL SINUS CARCINOMA; PAROTID GLAND CARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TH1 TH2 BALANCE; TREATMENT RESPONSE;

EID: 84855238145     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2011.12.001     Document Type: Article

References (29)

1. Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine 2010, 363:24-35.
2. Young M.R. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head and Neck 2006, 28:462-470.
3. Whiteside T.L. The tumour microenvironment and its role in promoting tumour growth. Oncogene 2008, 27:5904-5912.
4. Sparano A., Lathers DM, Achille N, Petruzzelli GJ, Young MR Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngology-Head and Neck Surgery 2004, 131:573-576.
5. Jebreel A., Mistry D., Loke D., et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. Journal of Laryngology and Otology 2007, 121:246-252.
6. Almand B., Resser J.R., Lindman B., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clinical Cancer Research 2000, 6:1755-1766.
7. Albers A.E., Strauss L., Liao T., Hoffman T.K., Kaufmann A.M. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clinical and Developmental Immunology 2010, 10.1155/2010/236378.
8. Schott A.K., Pries R., Wollenberg Permanent up-regulation of regulatory T-lymphocytes in patients with head and neck cancer. International Journal of Molecular Medicine 2010, 26:67-75.
9. Becker Y. Molecular immunological approaches to biotherapy of human cancers-a review, hypothesis and implications. Anticancer Research 2006, 26(2A):1113-1134.
10. Melinceanu L., Sarafoleanu C., Lerescu L., Tucureanu C., Caraş I., Sǎlǎgeanu A. Impact of smoking on the immunological profile of patients with laryngeal carcinoma. Journal of Medicine and Life 2009, 2:211-218.
11. Agarwal A., Agarwal U., Verma S., Mohanty N.K., Saxena S. Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy. Immunopharmacology and Immunotoxicology 2010, 32:348-356.
12. Nelson E.L., Wenzel L.B., Osann K., et al. Stress, immunity and cervical cancer: biobehavioural outcomes of a randomized clinical trial. Clinical Cancer Research 2008, 14:2111-2118.
13. Allen C., Duffy S., Teknos T., et al. Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clinical Cancer Research 2007, 13:3182-3190.
14. Bigbee Wl Grandis JR, Siegfried J.M. Mulitple cytokine and growth factor serum biomarkers predict therapeutic response and survival in advanced-stage head and neck cancer patients. Clinical Cancer Research 2007, 13:3107-3108.
15. Ginos M.A., Page G.P., Michalowicz B.S., et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Research 2004, 64:55-63.
16. Mann E.A., Spiro J.D., Chen L.L., Kreutzer D.L. Cytokine expression by head and neck squamous cell carcinomas. American Journal of Surgery 1992, 164:567-573.
17. Lathers D.M.R., Achille N.J., Young M.R.I. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Human Immunology 2003, 64:1160-1166.
18. Alhamarneh O., Agada F., Madden L., Stafford N., Greenman J. Serum IL10 and circulating CD4(+) CD25(high) regulatory T cell numbers as predictors of clinical outcome and survival in patients with head and neck squamous cell carcinoma. Head and Neck 2011, 33:415-423.
19. Bose A., Cakraborty T., Chakraborty K., Pal S., Baral R. Dysregulation in immune functions is reflected in tumour cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immunology 2008, 12:8-10.
20. Hoffmann T.K., Sonkoly E., Homey B., et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head and Neck 2007, 29:472-478.
21. Günaydin R.O., Kesikli S.A., Kansu E., Hoşal A.S. Identification of the peripheral blood levels of interleukin-12, interleukin-10, and transforming growth factor-Β in patients with laryngeal squamous cell carcinoma. Head and Neck 2011, [Epub ahead of print]. 10.1002/hed.21738.
22. Hoffman H.T., Karnell L.H., Funk G.F., Robinson R.A., Menck H.R. The National Cancer Data Base report on cancer of the head and neck. Archives of Otolaryngology-Head and Neck Surgery 1998, 124:951-962.
23. Freier K., Bosch F.X., Flechtenmacher C., et al. Distinct site specific oncoprotein over expression in head and neck squamous cell carcinoma: a tissue microarray analysis. Anticancer Research 2003, 23(5A):3971-3977.
24. Weinberger P.M., Merkley M., Lee J.R., et al. Use of combination proteomic analysis to demonstrate molecular similarity of head and neck squamous cell carcinoma arising from different subsites. Archives of Otolaryngology-Head and Neck Surgery 2009, 135:694-703.
25. Van Horssen R., Ten Hagan T.L., Eggermont A.M. TNF-α in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006, 11:397-408.
26. Papadoppulou E., Tripsianis G., Anagnostopoulos K., et al. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer. International Journal of Biological Markers 2010, 25:126-135.
27. Terabe M., Park J.M., Berzofsky J.A. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunology Immunotherapy 2004, 53:79-85.
28. Kawakami K., Kawakami M., Joshi B.H., Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Research 2001, 61:6194-6200.
29. Park J.O., Sun Di, Cho K.J., Joo Y.H., Yoo H.J., Kim M.S. Clinical outcome of squamous cell carcinoma of the tongue in young patients: a stage-matched comparative analysis. Clinical and Experimental Otorhinolaryngology 2010, 3:161-165.